Clinical TrialsQuoin Pharmaceuticals' lead asset, QRX003, is currently in Phase 3 studies for treating Netherton Syndrome and may be the first product to be approved for this indication.
Financing And Market PotentialThe recent financing of $16.5M upfront with potential for up to $104.5M reflects QRX003’s potential in treating Netherton Syndrome and extends Quoin's cash runway to complete its studies and advance its pipeline.
Regulatory AdvantagesQRX003 received Orphan Drug Designation by the FDA, which could facilitate the drug's development and approval process.